Jazz Pharmaceuticals expands sleep disorder drug portfolio with FDA approval of Xywav

The company already markets two other narcolepsy drugs that generated more than $1 billion in combined sales last year.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.